Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Dec 17
Have your own idea? Try our Stock Screener
Hong Kong (HSI) Clinical Research and Equipment Industry Analysis
UpdatedJan 20, 2025
DataAggregated Company Financials
Companies9
- 7D0.2%
- 3M-5.4%
- 1Y-31.6%
- YTDn/a
The Clinical Research and Equipment is pretty flat in the last 7 days, but WuXi Biologics (Cayman) has stood out, gaining 4.4%. As for the longer term, the industry has declined 32% in the last year. Earnings are forecast to grow by 41% annually.
Industry Valuation and Performance
Has the Hong Kong Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Mon, 20 Jan 2025 | HK$151.4b | HK$35.7b | -HK$1,061,648,583.22 | 54.6x | -142.6x | 4.2x |
| Wed, 18 Dec 2024 | HK$151.3b | HK$35.7b | -HK$1,057,810,224.42 | 58x | -143x | 4.2x |
| Fri, 15 Nov 2024 | HK$142.6b | HK$35.9b | -HK$1,058,198,890.49 | 44.8x | -134.8x | 4x |
| Sun, 13 Oct 2024 | HK$168.2b | HK$35.9b | -HK$654,984,778.47 | 30.3x | -256.8x | 4.7x |
| Tue, 10 Sep 2024 | HK$140.7b | HK$35.8b | -HK$661,927,365.64 | 23.9x | -212.6x | 3.9x |
| Thu, 08 Aug 2024 | HK$98.7b | HK$33.7b | HK$3.1b | 17.5x | 31.6x | 2.9x |
| Sat, 06 Jul 2024 | HK$88.3b | HK$33.4b | HK$3.1b | 19.4x | 28.7x | 2.6x |
| Mon, 03 Jun 2024 | HK$90.1b | HK$33.5b | HK$3.1b | 27.5x | 29.1x | 2.7x |
| Wed, 01 May 2024 | HK$111.9b | HK$33.6b | HK$3.1b | 29.4x | 36.2x | 3.3x |
| Fri, 29 Mar 2024 | HK$116.9b | HK$33.9b | HK$2.8b | 21.4x | 41.7x | 3.5x |
| Sun, 25 Feb 2024 | HK$134.5b | HK$32.3b | HK$3.0b | 54.2x | 45.2x | 4.2x |
| Tue, 23 Jan 2024 | HK$188.6b | HK$32.3b | HK$3.0b | 84.4x | 63.4x | 5.8x |
| Thu, 21 Dec 2023 | HK$209.8b | HK$32.4b | HK$3.0b | 90.7x | 69.9x | 6.5x |
| Sat, 18 Nov 2023 | HK$291.7b | HK$30.5b | HK$2.7b | 307x | 106.2x | 9.6x |
| Mon, 16 Oct 2023 | HK$262.3b | HK$30.1b | HK$2.7b | 46.9x | 98.2x | 8.7x |
| Wed, 13 Sep 2023 | HK$229.1b | HK$30.2b | HK$2.7b | 40.5x | 85.5x | 7.6x |
| Fri, 11 Aug 2023 | HK$238.3b | HK$28.4b | HK$2.7b | 23.6x | 87.6x | 8.4x |
| Sun, 09 Jul 2023 | HK$203.8b | HK$28.4b | HK$2.7b | 20.6x | 75.1x | 7.2x |
| Tue, 06 Jun 2023 | HK$232.4b | HK$28.8b | HK$2.8b | 20.8x | 83.6x | 8.1x |
| Thu, 04 May 2023 | HK$242.5b | HK$29.5b | HK$2.9b | 22.5x | 83x | 8.2x |
| Sat, 01 Apr 2023 | HK$250.0b | HK$29.1b | HK$2.5b | 22.4x | 101.6x | 8.6x |
| Mon, 27 Feb 2023 | HK$282.2b | HK$26.2b | HK$2.0b | 24.6x | 140.3x | 10.8x |
| Wed, 25 Jan 2023 | HK$371.2b | HK$26.6b | HK$2.1b | 27.8x | 174.2x | 13.9x |
| Fri, 23 Dec 2022 | HK$276.1b | HK$25.9b | HK$2.0b | 24.4x | 139.3x | 10.6x |
| Sun, 20 Nov 2022 | HK$270.2b | HK$25.6b | HK$1.9b | 26.1x | 142.7x | 10.5x |
| Tue, 18 Oct 2022 | HK$258.7b | HK$25.5b | HK$1.9b | 21.4x | 139.4x | 10.1x |
| Thu, 15 Sep 2022 | HK$269.6b | HK$26.3b | HK$2.0b | 24.1x | 132.4x | 10.3x |
| Sat, 13 Aug 2022 | HK$373.3b | HK$22.3b | HK$2.0b | 12.2x | 182.3x | 16.7x |
| Mon, 11 Jul 2022 | HK$422.1b | HK$22.4b | HK$2.1b | 14.6x | 202.4x | 18.8x |
| Wed, 08 Jun 2022 | HK$338.5b | HK$22.5b | HK$2.1b | 13.8x | 160.2x | 15x |
| Fri, 06 May 2022 | HK$281.5b | HK$22.7b | HK$2.2b | 13.1x | 130.8x | 12.4x |
| Sun, 03 Apr 2022 | HK$341.7b | HK$23.3b | HK$2.3b | 15.4x | 146.6x | 14.7x |
| Tue, 01 Mar 2022 | HK$350.5b | HK$18.8b | HK$2.8b | 20.3x | 123.2x | 18.6x |
| Thu, 27 Jan 2022 | HK$407.9b | HK$18.7b | HK$2.8b | 27.5x | 144.5x | 21.8x |
Price to Earnings Ratio
144.5x
Current Industry PE
- Investors are pessimistic on the Hong Kong Life Sciences Tools and Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 8.8x is higher than the industry's current PS ratio of 4.2x.
Past Earnings Growth
- Total earnings for the Life Sciences Tools and Services industry have declined over the last three years, with the industry now making a loss overall.
- Meanwhile revenues have grown 24% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Comparison
How does Hong Kong Clinical Research and Equipment compare with similar industries?
| HK Market | 2.14% | |
| Healthcare | 0.44% | |
| Life Sciences | 0.15% | |
| Clinical Research and Equipment | 0.15% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 2269 WuXi Biologics (Cayman) | HK$18.70 | 10.7% +HK$7.2b | -30.7% | PE27.4x | |
| 1548 Genscript Biotech | HK$9.91 | 10.1% +HK$2.0b | -35.7% | PS2.7x | |
| 2268 WuXi XDC Cayman | HK$30.25 | 4.7% +HK$1.6b | 0.5% | PE57.3x | |
| 1521 Frontage Holdings | HK$1.63 | 10.9% +HK$323.8m | -18.1% | PE69.5x | |
| 2228 XtalPi Holdings | HK$4.53 | 0.7% +HK$102.2m | n/a | PS73.6x |